# S1 Table. Reactogenicity to rVSV-ZEBOV vaccine until day 28.

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Adults** | **Children** | **Adolescent** |
| **Adverse** | **All adults** | **3x103 PFU, n=20** | **3x104 PFU, n=20** | **3x105 PFU\*, n=20** | **3x106 PFU\*, n=39** | **2x107 PFU, n=16** | **2x107 PFU, n=20** | **2x107 PFU,** **n=20** |
| **Events** | **N** | **E (%)** | **N** | **E (%)** | **N** | **E (%)** | **N** | **E (%)** | **N** | **E (%)** | **N** | **E (%)** | **N** | **E (%)** | **N** | **E (%)** |
| **Any event** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Mild | 76 | 234 (68) | 12 | 33 (64) | 10 | 26 (67) | 19 | 54 (65) | 28  | 97 (70) | 7 | 24 (75) | 18 | 87 (82) | 20 | 79 (81) |
| Moderate | 40 | 110 (32) | 7 | 19 (36) | 6 | 13 (33) | 11 | 29 (35) | 13 | 41 (30) | 3 | 8 (25) | 7 | 19 (18) | 6 | 19 (19) |
| **Solicited injection site reactions** |  |  |  |  |
| **Pain**  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Mild | 29 | 32 (91) | 3 | 4 (100) | 3 | 3 (75) | 3 | 3 (100) | 16 | 16 (100) | 4 | 6 (75) | 9 | 9 (75) | 8 | 8 (80) |
| Moderate | 3 | 3 (9) | 0 | 0 (0) | 1 | 1 (25) | 0 | 0 (0) | 0 | 0 (0) | 2 | 2 (25) | 2 | 3 (25) | 2 | 2 (20) |
| **Swelling**  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Mild | 0 | 0 (0) | 0 | 0 (0) | 0 | 0 (0) | 0 | 0 (0) | 0 | 0 (0) | 0 | 0 (0) | 0 | 0 (0) | 1 | 100 (0) |
| Moderate | 0 | 0 (0) | 0 | 0 (0) | 0 | 0 (0) | 0 | 0 (0) | 0 | 0 (0) | 0 | 0 (0) |  | 0 (0) | 0 | 0 (0) |
| **Solicited systemic reactions** | 0 |  |  |  |
| **Fatigue**  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Mild | 24 | 26 (72) | 3 | 3 (75) | 3 | 3 (100) | 7 | 7 (70) | 9 | 11 (69) | 2 | 2 (67) | 9 | 10 (83) | 3 | 3 (43) |
| Moderate | 10 | 10 (28) | 1 | 1 (25) | 0 | 0 (0) | 3 | 3 (30) | 5 | 5 (31) | 1 | 1 (33) | 2 | 2 (17) | 4 | 4 (57) |
| **Headache**  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Mild | 26 | 32 (68) | 5 | 6 (60) | 3 | 5 (100) | 6 | 7 (64) | 9 | 10 (63) | 3 | 4 (80) | 8 | 9 (90) | 11 | 13 (81) |
| Moderate | 13 | 15 (32) | 3 | 4 (40) | 0 | 0 (0) | 3 | 4 (36) | 6 | 6 (37) | 1 | 1 (20) | 1 | 1 (10) | 3 | 3 (19) |
| **Myalgia** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Mild | 9 | 9 (64) | 2 | 2 (67) | 0 | 0 (0) | 1 | 1 (50) | 6 | 6 (67) | 0 | 0 (0) | 3 | 3 (75) | 5 | 5 (83) |
| Moderate | 5 | 5 (36) | 1 | 1 (33) | 0 | 0 (0) | 1 | 1 (50) | 3 | 3 (33) | 0 | 0 (0) | 1 | 1 (25) | 1 | 1 (17) |
| **Subjective fever**  |  |  |  |  |
| Mild | 16 | 18 (78) | 1 | 1 (50) | 2 | 2 (50) | 1 | 2 (100) | 9 | 10 (83) | 3 | 3 (100) | 7 | 9 (90) | 7 | 9 (90) |
| Moderate | 5 | 5 (22) | 1 | 1 (50) | 2 | 2 (50) | 0 | 0 (0) | 2 | 2 (17) | 0 | 0 (0) | 1 | 1 (10) | 1 | 1 (10) |
| **Objective fever**  |  |  |  |  |  |
| Mild | 10 | 11 (85) | 3 | 4 (100) | 1 | 1 (100) | 1 | 1 (100) | 3 | 3 (60) | 2 | 2 (100) | 7 | 7 (100) | 5 | 5 (100) |
| Moderate | 1 | 2 (15) | 0 | 0 (0) | 0 | 0 (0) | 0 | 0 (0) | 2 | 2 (40) | 0 | 0 (0) | 0 | 0 (0) | 0 | 0 (0) |
| **Chill**s |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Mild | 3 | 3 (100) | 0 | 0 (0) | 0 | 0 (0) | 0 | 0 (0) | 3 | 3 (100) | 0 | 0 (0) | 5 | 5 (100) | 3 | 3 (100) |
| Moderate | 0 | 0 (0) | 0 | 0 (0) | 0 | 0 (0) | 0 | 0 (0) | 0 | 0 (0) | 0 | 0 (0) | 0 | 0 (0) | 0 | 0 (0) |
| **Arthralgia** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Mild | 7 | 8 (38) | 1 | 1 (20) | 0 | 0 (0) | 0 | 0 (0) | 5 | 6 (60) | 1 | 1 (33) | 3 | 3 (75) | 3 | 3 (75) |
| Moderate | 12 | 13 (61∙9) | 3 | 4 (80) | 1 | 1 (100) | 2 | 2 (100) | 4 | 4 (40) | 2 | 2 (66∙7) | 1 | 1 (25) | 1 | 1 (25) |
| **Mouth ulcer** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Mild | 4 | 4 (80) | 0 | 0 (0) | 0 | 0 (0) | 1 | 1 (100) | 2 | 2 (100) | 1 | 1 (50) | 1 | 1 (50) | 0 | 0 (0) |
| Moderate | 1 | 1 (20) | 0 | 0 (0) | 0 | 0 (0) | 0 | 0 (0) | 0 | 0 (0) | 1 | 1 (50) | 1 | 1 (50) | 0 | 0 (0) |
| **Skin lesion** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Mild | 6 | 6 (75) | 0 | 0 (0) | 1 | 1 (100) | 1 | 1 (100) | 0 | 0 (0) | 4 | 4 (80) | 1 | 1 (100) | 2 | 2 (100) |
| Moderate | 2 | 2 (25) | 0 | 0 (0) | 0 | 0 (0) | 0 | 0 (0) | 1  | 1 (100) | 1  | 1 (20) | 0 | 0 (0) | 0 | 0 (0) |
| **Blister** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Mild | 1 | 1 (100) | 0 | 0 (0) | 0 | 0 (0) | 0 | 0 (0) | 0 | 0 (0) | 1 | 1 (100) | 0 | 0 (0) | 0 | 0 (0) |
| Moderate | 0 | 0 (0) | 0 | 0 (0) | 0 | 0 (0) | 0 | 0 (0) | 0 | 0 (0) | 0 | 0 (0) | 0 | 0 (0) | 0 | 0 (0) |
| **Gastrointestinal symptoms** |  |  |  |  |
| Mild | 24 | 27 (77) | 3 | 3 (100) | 3 | 3 (50) | 7 | 8 (73) | 8 | 10 (83) | 3 | 3 (100) | 9 | 12 (80) | 6 | 10 (77) |
| Moderate | 5 | 8 (23) | 0 | 0 (0) | 1 | 3 (50) | 3 | 3 (27) | 1 | 2 (17) | 0 | 0 (0) | 2 | 3 (20) | 3 | 3 (23) |
| **Unsolicited adverse events** |  |  |  |  |
| **Malaria** |  |  |  |  |  |
| Mild | 6 | 6 (29) | 1 | 1 (100) | 0 | 0 (0) | 0 | 0 (0) | 0 | 0 (0) | 5 | 5 (56) | 0 | 0 (0) | 2 | 2 (67)  |
| Moderate | 12 | 15 (71) | 0 | 0 (0) | 0 | 0 (0) | 5 | 6 (100) | 3 | 5 (100) | 4 | 4 (44) | 2 | 2 (100) | 1 | 1 (33) |
| **Rhinitis** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Mild | 10 | 10 (100) | 2 | 2 (100) | 1 | 1 (100) | 2 | 2 (100) | 1 | 1 (100) | 4 | 4 (100)  | 1 | 1 (100) | 3 | 3 (100)  |
| Moderate | 0 | 0 (0) | 0 | 0 (0) | 0 | 0 (0) | 0 | 0 (0) | 0 | 0 (0) | 0 | 0 (0) | 0 | 0 (0) | 0 | 0 (0) |
| **Cough** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Mild | 12 | 14 (78) | 4 | 4 (57) | 2 | 3 (75) | 1 | 1 (100) | 1 | 1 (100) | 4 | 4 (100)  | 2 | 2 (100) | 0 | 0 (0) |
| Moderate | 4 | 4 (22) | 3 | 3 (43) | 1 | 1 (25) | 0  | 0 (0) | 0  | 0 (0) | 0 | 0 (0) | 0 | 0 (0) | 0 | 0 (0) |
| **Other** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Mild | 60 | 87 (64)  | 3 | 5 (42) | 6 | 11 (65) | 16 | 22 (69) | 18 | 25 (61) | 17 | 24 (71) | 8 | 11 (85) | 6 | 8 (100) |
| Moderate | 33 | 49 (36) | 4 | 7 (58) | 5 | 6 (35) | 7 | 10 (31) | 9  | 16 (39) | 8 | 10 (29) | 2 | 2 (15) | 0 | 0 (0) |
| **N: Number of participants reporting at least one event per dose irrespective of grade.****E: Indicates all events reported per cohort****%: Percentage of events reported****\*Already partially reported in the New England Journal of Medicine, DOI: 10∙1056/NEJMoa1502924 (3x105 PFU n = 20 and 3x106 PFU n = 19)∙** |